Related references
Note: Only part of the references are listed.DONEPEZIL IMPROVES LEARNING AND MEMORY DEFICITS IN APP/PS1 MICE BY INHIBITION OF MICROGLIAL ACTIVATION
H. B. Guo et al.
NEUROSCIENCE (2015)
EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques
Hye Yun Kim et al.
NATURE COMMUNICATIONS (2015)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Disease-modifying treatments for Alzheimer’s disease
Daniela Galimberti et al.
Therapeutic Advances in Neurological Disorders (2011)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence
I. A. Lockhart et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2009)
Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease
Dongfeng Cao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Lateral scanning confocal microscopy for the determination of in-plane displacements of microelectromechanical systems devices
Zhi Li et al.
OPTICS LETTERS (2007)
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial
PN Tariot et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease - A meta-analysis
NH Trinh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Share Paper
